Literature DB >> 25346470

Monitoring treatment response in patients undergoing chemoradiotherapy for locally advanced uterine cervical cancer by additional diffusion-weighted imaging: A systematic review.

Sanne M Schreuder1, Rutger Lensing1, Jaap Stoker1, Shandra Bipat1.   

Abstract

PURPOSE: To determine the role of diffusion-weighted imaging (DWI) in evaluating response to chemoradiotherapy in patients with uterine cervical cancer.
MATERIALS AND METHODS: A search was performed in MEDLINE and EMBASE from January 2005 to April 2014 using search terms related to uterine cervical cancer and magnetic resonance imaging. Two reviewers independently checked the studies for inclusion criteria, patient population, magnetic resonance imaging (MRI) parameters and analysis, follow-up for treatment response, apparent diffusion coefficient (ADC) values, and quality assessment.
RESULTS: Nine studies with 231 patients were included. International Federation of Gynecology and Obstetrics (FIGO) staging varied from Ib1 to IVb and mean age from 42 to 67 years. When baseline and after treatment pooled mean ADC values were compared, complete responders showed higher increase (0.88 × 10(-3) mm(2) /s to 1.50 × 10(-3) mm(2) /s; Δ0.62 × 10(-3) mm(2) /s) compared to partial responders (1.03 × 10(-3) mm(2) /s to 1.42 × 10(-3) mm(2) /s; Δ0.39 × 10(-3) mm(2) /s) and to nonresponders (0.87 × 10(-3) mm(2) /s to 1.18 × 10(-3) mm(2) /s; Δ0.31 × 10(-3) mm(2) /s). Individual studies also showed that an ADC of ≤0.31 was only seen in nonresponders and an increase of ADC of ≥0.62 was only seen in complete responders. The number of datasets for monitoring early response (at 2 or 4 weeks of therapy) were low and comparable increases in pooled mean ADC values between complete responders, partial responders, and nonresponders were seen. Data on quality assessment showed high risk of bias concerning patient selection, DWI evaluation, and flow and timing.
CONCLUSION: DWI can be used for monitoring treatment response after treatment, but not for the early response monitoring.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  cervix neoplasm; diffusion weighted imaging; magnetic resonance imaging; response monitoring

Mesh:

Year:  2014        PMID: 25346470     DOI: 10.1002/jmri.24784

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  28 in total

1.  The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.

Authors:  A L Valentini; M Miccò; B Gui; M Giuliani; E Rodolfino; A M Telesca; T Pasciuto; A Testa; M A Gambacorta; G Zannoni; V Rufini; A Giordano; V Valentini; G Scambia; R Manfredi
Journal:  Eur Radiol       Date:  2018-01-09       Impact factor: 5.315

2.  Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018.

Authors:  Lucia Manganaro; Yulia Lakhman; Nishat Bharwani; Benedetta Gui; Silvia Gigli; Valeria Vinci; Stefania Rizzo; Aki Kido; Teresa Margarida Cunha; Evis Sala; Andrea Rockall; Rosemarie Forstner; Stephanie Nougaret
Journal:  Eur Radiol       Date:  2021-04-14       Impact factor: 5.315

3.  Radiomic ADC Metrics as a Tool to Better Understand Tumor Biology.

Authors:  Caroline Reinhold; Stephanie Nougaret
Journal:  Radiol Imaging Cancer       Date:  2020-05-22

4.  A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-small cell lung cancer.

Authors:  Yukinori Matsuo
Journal:  Transl Lung Cancer Res       Date:  2018-04

5.  Prediction of disease progression following concurrent chemoradiotherapy for uterine cervical cancer: value of post-treatment diffusion-weighted imaging.

Authors:  Jung Jae Park; Chan Kyo Kim; Byung Kwan Park
Journal:  Eur Radiol       Date:  2015-12-18       Impact factor: 5.315

6.  Volume Delineation in Cervical Cancer With T2 and Diffusion-weighted MRI: Agreement on Volumes Between Observers.

Authors:  Consuelo Rosa; Andrea Delli Pizzi; Antonietta Augurio; Luciana Caravatta; Monica DI Tommaso; Erica Mincuzzi; Sebastiano Cinalli; Raffaella Basilico; Annamaria Porreca; Marta DI Nicola; Domenico Genovesi
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 7.  Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.

Authors:  Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow
Journal:  J Magn Reson Imaging       Date:  2016-08-16       Impact factor: 4.813

8.  Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.

Authors:  Michele Anzidei; Alessandro Napoli; Beatrice Sacconi; Fabrizio Boni; Vincenzo Noce; Michele Di Martino; Luca Saba; Carlo Catalano
Journal:  Radiol Med       Date:  2016-08-27       Impact factor: 3.469

Review 9.  Diffusion weighted imaging in gynecological malignancies - present and future.

Authors:  Dinesh Manoharan; Chandan J Das; Ankita Aggarwal; Arun K Gupta
Journal:  World J Radiol       Date:  2016-03-28

Review 10.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.